These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 19569254)

  • 1. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
    Rau R; Brown P
    Hematol Oncol; 2009 Dec; 27(4):171-81. PubMed ID: 19569254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incidence and clinical significance of nucleophosmin mutations in childhood AML.
    Brown P; McIntyre E; Rau R; Meshinchi S; Lacayo N; Dahl G; Alonzo TA; Chang M; Arceci RJ; Small D
    Blood; 2007 Aug; 110(3):979-85. PubMed ID: 17440048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
    Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
    Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
    Falini B; Nicoletti I; Martelli MF; Mecucci C
    Blood; 2007 Feb; 109(3):874-85. PubMed ID: 17008539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
    Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques.
    Chopra A; Soni S; Pati H; Kumar D; Diwedi R; Verma D; Vishwakama G; Bakhshi S; Kumar S; Gogia A; Kumar R
    Indian J Med Res; 2016 Jun; 143(6):763-768. PubMed ID: 27748301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.
    Tan AY; Westerman DA; Carney DA; Seymour JF; Juneja S; Dobrovic A
    J Hematol Oncol; 2008 Jul; 1():10. PubMed ID: 18664261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of cytoplasmic nucleophosmin in formalin-fixed paraffin-embedded marrow trephine biopsies in acute myeloid leukaemia.
    Lit BM; Kwong YL; Wong KF
    J Clin Pathol; 2016 May; 69(5):409-14. PubMed ID: 26500335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
    Falini B
    Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
    Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1749-1755. PubMed ID: 31244296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of FLT3-ITD mutation on NPM1
    Pan X; Chang Y; Ruan G; Wei F; Jiang H; Jiang Q; Huang X; Zhao X
    Br J Haematol; 2023 Oct; 203(2):212-223. PubMed ID: 37621257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
    Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
    Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
    Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.
    Rau R; Magoon D; Greenblatt S; Li L; Annesley C; Duffield AS; Huso D; McIntyre E; Clohessy JG; Reschke M; Pandolfi PP; Small D; Brown P
    Exp Hematol; 2014 Feb; 42(2):101-13.e5. PubMed ID: 24184354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.